{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-007816","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.144066+00:00","generated_at":"2026-05-26T04:56:38.619124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M","bullets":["Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.","GAAP net loss $(108)M vs $(212)M in Q4 2023; Adj EBITDA $(57)M vs $(101)M.","Cash flow $(55)M in Q4, improved from $(114)M in Q3; cash balance $562M.","FY2025 guidance: total revenue $160-180M, Cell Engineering $110-130M, Biosecurity at least $50M.","Cost-cutting achieved $190M annualized run-rate savings; targeting $250M by Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-007816","json":"https://secwatch.observer/filing/0001628280-25-007816.json","markdown":"https://secwatch.observer/filing/0001628280-25-007816.md","text":"https://secwatch.observer/filing/0001628280-25-007816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/0001628280-25-007816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/dna-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:56:38.619124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}